class=”sc-29f61514-0 fQbOYE”>
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rapidly growing form of non-Hodgkin lymphoma (NHL) and one of the most common types of blood cancer in adults, according to a Roche statement released Tuesday.
Columvi is the first antibody of its kind with a fixed duration of action that can be used for the treatment of patients with aggressive lymphoma who have received multiple treatments.
Roche received US approval for this cancer treatment less than a month ago. At the time, analysts had a very positive response, describing Columvi as a real alternative to other types of therapy, such as personalized CAR T-cell therapy.
(SDA)
Source :Blick
I’m Tim David and I work as an author for 24 Instant News, covering the Market section. With a Bachelor’s Degree in Journalism, my mission is to provide accurate, timely and insightful news coverage that helps our readers stay informed about the latest trends in the market. My writing style is focused on making complex economic topics easy to understand for everyone.
